

What have we learned?

- Flexibility
- Healthcare staffing is a challenge
- Most people want to do the right thing
- Asymptomatic transmission happens
 - 15 – 40% of people are asymptomatic in NH (varies by age)
- Masks and social distancing work
- People relax precautions around friends and family

Vaccine Planning

- Statewide Vaccination [Plan](#) Submitted to CDC
- Current Vaccine Frontrunners:
 - Pfizer
 - Moderna
- Vaccine Allocation Timeline:
 - Could have vaccine in early December
- Leveraging existing plans and H1N1 experience

Thank you!

Beth Daly, MPH

Bureau of Infectious Disease Control

29 Hazen Drive, Concord, NH 03301


603-271-4927

elizabeth.daly@dhhs.nh.gov

Bureau of Infectious Disease Control

603-271-4496 (after-hours: 603-271-5300)

nhbidc@dhhs.nh.gov



COVID-19 Vaccine for New Hampshire

Elizabeth Talbot, MD

Deputy State Epidemiologist, NH DHHS

*Vaccine Allocation Strategy Branch Chief, Public Health
COVID-19 Response*

*Professor, Infectious Diseases and International Health,
Dartmouth*

The Candidates

Brief Overview








Coronavirus Vaccine Tracker

By Jonathan Corum, Sui-Lee Wee and Carl Zimmer Updated October 29, 2020



<https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>

Selected COVID-19 Vaccine Candidates

Platform	Developer	Phase 1/2	Phase 2/3
Nucleic acid		Enrolled	Ongoing
		Enrolled	Ongoing
Viral vector		Enrolled	Ongoing
		Enrolled	Ongoing
		Ongoing	--
Protein subunit		Ongoing	Ongoing
		Ongoing	--

Most Advanced US Candidates

Vaccine	Platform	Ph 3	Updates
Moderna NIH	2-dose (21d) mRNA (-20C)	July 27	July: Patent dispute lost Oct 23: completed ph3 EUA subm mid-Dec
Pfizer BioNTech Fosun Pharma	2-dose (28d) mRNA (-70C)	July 27	Sept 12: expanded to 43k Target analysis Oct 2020 EUA subm 3 rd week Nov
Johnson and Johnson	1-dose Ad26 (~Ebola)	Sept	Oct 12 pause for AE
AstraZeneca Oxford	2-dose (28d) ChadOx1	July	Sept 6 pause for AE Oct 23 restarted in US
Novavax	2-dose (21d) Protein subunit (nanotech)	Sept in UK End Nov in US	Early 2021 results

Any 2-dose series has to be with the same vaccine

How to Allocate Limited Supply?

Ethics, equity, logistics

Vaccine Allocation: Timeline – Best Estimate

Pfizer 3rd week of November
Moderna early-mid December

Submit vaccine dossier
to FDA and request
Emergency Use
Authorization (EUA)

~2 weeks later

FDA approval

Vaccines & Related
Biological Products
Advisory Committee
(VRBPAC) reviews EUA
request to make
recommendation to FDA

ACIP to hold emergency
meeting within 24 hours
of FDA authorization

Pfizer could be ready 1st
week of December.
Moderna ready in late Dec.




FIGURE 1-2 Operation Warp Speed vaccine distribution process.
SOURCE: HHS, 2020b.

Phases of Vaccine Distribution

Distribution will Adjust as volume of vaccine doses increases, moving from targeted to broader populations reached (phased approach)

